BioWorld

Jan. 2, 2007

Neuralstem Lists On OTCBB, To Start Clinical Trials Soon

As a stem cell company preparing to enter clinical trials in 2007, Neuralstem Inc. began trading last week on the Over-the-Counter Bulletin Board. (BioWorld Today) Read More

Viragen Signs Australian Partner For Multiferon In Skin Cancer

Unintended Consequences: Mother Nature vs. Innovation

Following The Money Leads To Clinical Trials In Rare Cancer

Holiday Notice

BioWorld's offices are closed Monday, Jan. 1, in observance of the New Year's Day holiday in the U.S. No issue will be published. Read More

Other News To Note

Appointments And Advancements

Market updates: AHA report — ‘99-’05 heart disease, stroke show big decrease

Today's news in brief

BioWorld

BioWorld briefs for Dec. 17, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 17, 2024.

Second insulin receptor offers new therapeutic avenues

BioWorld Science

Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...

Drug duo to Repare lack in gyno cancers? Phase I shows promise

BioWorld

Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

Mechanism underlying so-called idiopathic autism inception unveiled

BioWorld Science

Investigators at the Institute for Research in Biomedicine (IRB Barcelona) have unraveled how and why the absence of a neuronal microexon in cytoplasmic...